- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03622827
Postoperative Concurrent Chemoradiotherapy Combined With Endostar for High-risk Early Stage Cervical Cancer (ChESS)
Postoperative Concurrent Chemoradiotherapy Combined With Recombinant Human Endostatin for High-risk Early Stage Cervical Cancer: A Phase II Pilot Study (ChESS).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a pilot phase 2, single arm study to assess the efficacy and safety of concurrent chemoradiotherapy combined with recombinant human endostatin (Endostar) in early stage cervical cancer patients with high risk factor(s).
Postoperative pelvic radiotherapy starts 2-3 weeks after surgery. Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total prescription dose of 45-50Gy to PTV region. The external beam radiotherapy should be completed within 6 weeks. Concurrent chemotherapy consists of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day, civ, day 1-4) for 2 cycles every 3 weeks. Recombinant human endostatin (Endostar,15mg/m2/d, civ, d1-7) is applied 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks.
Aimed to recruit total of 120 cases in this single arm study. The primary endpoint is 3-year disease-free survival and acute toxicity. Secondary endpoints include time to distant metastasis survival, local-regional recurrence free survival, 3 and 5-year overall survival, and safety and tolerability. Quality of life will be evaluated with EORTC-Q30.
Tipo di studio
Iscrizione (Anticipato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Ke Gu, M.D., Ph.D
- Numero di telefono: 86-13405070898
- Email: dr.guke@hotmail.com
Backup dei contatti dello studio
- Nome: Zhiliang Ding, M.D.
- Numero di telefono: 86-18913535515
Luoghi di studio
-
-
Jiangsu
-
Suzhou, Jiangsu, Cina, 215001
- Reclutamento
- The Affiliated Suzhou Hospital of Nanjing Medical University
-
Contatto:
- Ke Gu, M.D., Ph.D
- Numero di telefono: 86-13405070898
- Email: dr.guke@hotmail.com
-
Contatto:
- Zhiliang Ding, M.D.
- Numero di telefono: 86-18913535515
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Aged between 18 and 70 years.
- Histologically confirmed adenocarcinoma or squamous cervical carcinomas.
- Chest CT scan and ultrasound must be done prior to surgery as to rule out distant metastasis.
- Operable patients with clinical diagnosis of FIGO stage IB-IIA cervical cancer.
- Complete radical hysterectomy of cervical cancer is mandatory. All gross diseases must have been removed at the end of surgery. All surgical margins of resection must be negative for tumor. Para-aortic lymph node sampling is performed according to gynaecologist decision.
- Patients with one of these risk factors:positive pelvic nodes, parametrial invasion, positive surgical margin.OR patients with at least two of following risk factors: tumor size≥4cm,lymphovascular space invasion,stromal invasion≥1/2.
- Performance status 0-2 (ECOG, Eastern Cooperative Oncology Group).
- Adequate organ function is needed, including cardio-respiratory, hepato-renal and hematological reserves: Absolute neutrophil count (ANC)≥1.5×109/L;Platelet count≥100×109/L; ASAT&ALST<1.5 times upper limit of normal (ULN) (With hepatic metastases, ASAT&ALST<5.0 times upper limit of normal);Bilirubin <1.5 times ULN;Creatinine≤1.25×ULN or Creatinine clearance≥50 mL/min.
- Signed written informed consent prior to study entry.
Exclusion Criteria:
- Previous radiation or chemotherapy treatment or major pelvic surgery.
- Patients with distant metastasis confirmed by imaging or pathology.
- Other uncured malignant tumors in the past five years, except the cured skin basal cell carcinoma and breast carcinoma in situ.
- Any prior anticancer therapy.
- Unable to tolerate postoperative concurrent chemoradiotherapy.
- Patients with evidence of being allergic to fluorouracil, cisplatin or Endostar.
- Patients with serious comorbidity that might potentially influence the practice of protocol, including severe infection, myocardial infarction, severe arrhythmia, severe cerebrovascular disease, severe mental disorder, etc.
- Patients with Heart related adverse events or thrombotic events in the past 6 months.
- Patients with hepatitis B, hepatitis C and human immunodeficiency virus (HIV) or any other active viral infections.
- Participate in other clinical researchers.
- The estimated survival<3 months;
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Chemoradiotherapy + Endostar
Chemoradiotherapy with Endostar:
|
Chemoradiotherapy with Endostar:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
3-year Disease-free survival
Lasso di tempo: 3 years
|
From date of surgery until the date of first documented local-regional progression or distant metastasis (determined by CT or MRI scan and/or biopsy) or death (from any cause) assessed up to three years.
|
3 years
|
Acute toxicity
Lasso di tempo: 3 months
|
Evaluate the treatment induced toxicity according to CTCAE 4.0 during the time of chemoradiotherapy and Endostar which starts from the first day of Endostar and lasts three months.
|
3 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Time to distant metastasis survival
Lasso di tempo: 3 years
|
Determine the non-distant metastasis survival in early-stage cervical cancer patients with high risk factors, defined as time from the date of surgery to first distant metastasis event (determined by CT or MRI scan and/or pathologic disease on biopsy).
|
3 years
|
Local-regional recurrence free survival
Lasso di tempo: 3 years
|
Determine the local-regional recurrence free survival in early-stage cervical cancer patients with high risk factors, defined as time from the date of surgery to first local-regional recurrence event (determined by CT or MRI scan and/or pathologic disease on biopsy).
|
3 years
|
3-year overall survival rate
Lasso di tempo: 3 years
|
Determine the 3-year overall survival rate in early-stage cervical cancer patients with high risk factors, defined as time from the date of surgery to death of all cause at time of 3 years after operation.
|
3 years
|
5-year overall survival rate
Lasso di tempo: 5 years
|
Determine the 5-year overall survival rate in early-stage cervical cancer patients with high risk factors, defined as time from the date of surgery to death of all cause at time of 5 years after operation.
|
5 years
|
Quality of Life (QoL)
Lasso di tempo: 3 years
|
Collect QoL data on early-stage cervical cancer patients with high risk factors.
The data is measured by EORTC QLQ-C30 (Version 3.0) according to investigator collection at the starting and ending time of the adjuvant treatment.
EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients.
The core and disease-specific for cervix modules are selected to estimate treatment related influence on patients' life.
The final score of the questionnaire is collected and analyzed according to detailed scoring procedures from manuals.
|
3 years
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Ke Gu, M.D., Ph.D, The Affiliated Suzhou Hospital of Nanjing Medical University
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie uterine
- Neoplasie genitali, femmina
- Malattie della cervice uterina
- Malattie uterine
- Neoplasie cervicali uterine
- Effetti fisiologici delle droghe
- Agenti antineoplastici
- Inibitori dell'angiogenesi
- Agenti di modulazione dell'angiogenesi
- Sostanze per la crescita
- Inibitori della crescita
- Proteina endostellare
Altri numeri di identificazione dello studio
- K2018009
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Neoplasie cervicali uterine
-
Zagazig UniversityNon ancora reclutamentoCervical IO Plasty nella gestione della placenta previa
Prove cliniche su Chemoradiotherapy+ Endostar
-
Eastern Hepatobiliary Surgery HospitalCompletatoCarcinoma epatocellulare | Trombo del tumore della vena portaCina
-
Affiliated Hospital of North Sichuan Medical CollegeJiangsu Simcere Pharmaceutical Co., Ltd.Sconosciuto
-
Simcere Pharmaceutical Co., LtdThe Affiliated Changzhou Tumor Hospital of Suzhou UniversitySconosciutoNeoplasie colorettaliCina
-
Tianjin Medical University Cancer Institute and...CompletatoSarcoma dei tessuti molli, adulto, stadio IIBCina
-
Shanghai Jiao Tong University School of MedicineSconosciutoCancro colorettale avanzatoCina
-
Rennes University HospitalReclutamentoTest clinico | Case di cura | CiboFrancia
-
Yuhong LiCompletatoCarcinoma a cellule squamose dell'esofagoCina
-
Yun-fei XiaSconosciuto
-
Simcere Pharmaceutical Co., LtdSconosciutoMelanoma avanzato | Pazienti non trattatiCina